Bernie Sanders calls on FDA to allow generic, low cost versions of Catalyst Pharma’s $375,000 rare disease drug
March 1, 2019Medical Communications Bernie Sanders, Catalyst Pharmaceuticals Jacobus
US Senator Bernie Sanders has called on regulators to allow pharmacies and manufacturers to distribute generic versions of Catalyst Pharmaceuticals’ …
J&J sign deal with Scottish firm AdoRx to develop novel lung cancer treatments
March 1, 2019Medical Communications AdoRx, Cancer, Cancer Immunotherapy, J&J, JJ, immunology, oncology
Edinburgh-based drug discovery firm AdoRx therapeutics has signed a deal with US healthcare conglomerate Johnson & Johnson to develop novel …
Philippines Department of Justice recommends charges against six Sanofi officials
March 1, 2019Medical Communications Philippines, Sanofi, dengue, dengvaxia, vaccines
The Philippine Justice Ministry has said it has found probably cause to charge officials working for French drugmaker Sanofi over …
Nearly half of childhood cancer cases go untreated and undiagnosed
March 1, 2019Medical Communications Cancer, childhood cancer, diagnosis, oncology, pediatric, world
Almost half of all children with cancer are going untreated and undiagnosed, according to research published in Lancet Oncology. While …
Working Life: Nicola Redfern, UK General Manager, bluebird bio
February 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bluebird Bio, Interview, Working Life, pharma
How did you find your way into the pharma industry? Was it always an aspiration of yours? My mum worked …
Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt
February 28, 2019Sales and Marketing Bristol-Myers Squibb, Celgene, acquisition, pharma
The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, …
More than 40% of GPs intend to quit within five years
February 28, 2019Medical Communications GPs, NHS, NHS LOng term plan, UK, brexit, workforce
More than 40% of GPs intend to quit within five years according to researchers at the University of Warwick. The …
Trump ex-lawyer Cohen reveals Novartis pushed him to lobby
February 28, 2019Sales and Marketing Donald Trump, Michael Cohen, Novartis, US, pharma
Among the swirling storm emanating from the testimony of Donald Trump’s ex-lawyer Michael Cohen to the House Oversight Committee, one …
Scientists genetically modify yeast to produce CBD and THC
February 28, 2019Research and Development Medical marijuana, berkely, cannabis, science, yeast
Researchers at the University of California, Berkeley have genetically modified brewer’s yeast so that it produces two common cannabinoids: tetrahydrocannabinol …
Patients to recieve MDMA-assisted psychotherapy on ‘compassionate’ grounds in Israel
February 28, 2019Research and Development MDMA, PTSD, drugs, mental health, psychedelics
The Israeli Health Ministry has approved the compassionate use of MDMA-assisted psychotherapy for 50 patients with post-traumatic stress disorder (PTSD). …
Darknet sales of prescription psychiatric drugs increasing in the UK
February 27, 2019Research and Development, Sales and Marketing King's College London, Kings College London, University of Kent, darknet, pharma
Research from the University of Kent and King’s College London has revealed that UK sales of prescription psychiatric drugs, including …
Vaccine biotech Emergex name experienced pharma professional Dr Athanasios Papadopoulos as new CMO
February 27, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Emergex Vaccine Holdings Limited has named Dr Athanasios Papadopoulos as the company’s new Chief Medical Officer (CMO). The appointment, effective …
Pharma execs testify in front of Senate of rising drug prices
February 27, 2019Research and Development Business, Senate hearing, USA, pharma, sfc
Senior Executives from seven major pharmaceutical companies, including AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi and Johnson & …
Sanofi’s Dupixent improves symptoms in rhinosinusitis with nasal polyps at Phase 3
February 27, 2019Research and Development Dupixent, Sanofi, pharma, rhinosinusitis
New data has been released on Sanofi’s Dupixent (dupilumab), derived from two Phase 3 trials, illustrating the drug’s efficacy In …
British scientist develops technology able to deliver drugs directly into the brain
February 27, 2019Research and Development device, medical technology, neurology, neuroscince, parkinson's cns
A British scientist has developed innovative technology that is able to deliver drugs deep into the brain in order to …
Professor Patrick Chinnery named as Clinical Director of MRC
February 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Professor Patrick Chinnery has been appointed to the role of Clinical Director at the Medical Research Council (MRC) the non-departmental …
Read the March 2019 issue of Pharmafocus online now!
February 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Drug pricing, HIV, Trump, WHO, brexit, depression, mental health, pharmacovigilance, rare disease
Just one month to go until Brexit here in the UK, and it’s still all to play for. After months …
Jury upholds Amgen’s patent validity for Repatha, deflecting challenge from Sanofi and Regeneron
February 26, 2019Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, patent, pharma
Amgen is celebrating after a Delaware jury backed the validity of two of its patents against challenges from Regeneron and …
Vitamin D deficiency may cause cognitive decline through weakening brain’s scaffolding
February 26, 2019Manufacturing and Production NPP, mental health, neurology, neuroscience, schizophrenia, vitamin d
Vitamin D deficiency may weaken supportive ‘scaffolding’ in the brain thus causing neurons difficulty in maintaining connections, according to a …
Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer
February 26, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma
AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
